title: The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate.
abstract: OBJECTIVE
  The aim of our study is to find out the good responders for estramustine phosphate (EMP) therapy in patients with prostate cancer. We have focused on the metabolism of EMP and studied the association between a functional single-nucleotide polymorphism in the catechol-O-methyltransferase gene (Val158Met of COMT) and PSA-progression-free survival in Japanese patients with prostate cancer treated by EMP.
  
  
  METHODS
  Seventy-two Japanese patients with previously untreated prostate cancer who were found to be eligible for low-dose EMP therapy were enrolled in the study. Genotyping of the Val158Met polymorphism of COMT was conducted by both the polymerase chain reaction-based restriction fragment length polymorphism method and TaqMan assay.
  
  
  RESULTS
  Patients with the Val/Val genotype of COMT had a significantly higher PSA-progression-free rate as compared to those with the Val/Met or Met/Met genotype (p=0.027). The adjusted hazard ratio of biochemical PSA failure for the Val158Met genotype of COMT was 2.164 (95% CI, 1.111 to 5.525).
  
  
  CONCLUSIONS
  The Val158Met polymorphism of COMT is associated with the PSA-progression-free rate of EMP-treated patients in prostate cancer.
authors.affiliation: Department of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. suzukim-uro@h.u-tokyo.ac.jp
authors.forename: Motofumi
authors.initials: M
authors.lastname: Suzuki
authors.forename: Mohammed Rafiqul Islam
authors.initials: MR
authors.lastname: Mamun
authors.forename: Kazuo
authors.initials: K
authors.lastname: Hara
authors.forename: Takeshi
authors.initials: T
authors.lastname: Ozeki
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Yamada
authors.forename: Takashi
authors.initials: T
authors.lastname: Kadowaki
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Honda
authors.forename: Yoshitsugu
authors.initials: Y
authors.lastname: Yanagihara
authors.forename: Yoichi Minagawa
authors.initials: YM
authors.lastname: Ito
authors.forename: Shuji
authors.initials: S
authors.lastname: Kameyama
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Ohta
authors.forename: Takayuki
authors.initials: T
authors.lastname: Hosoi
authors.forename: Tomio
authors.initials: T
authors.lastname: Arai
authors.forename: Motoji
authors.initials: M
authors.lastname: Sawabe
authors.forename: Takumi
authors.initials: T
authors.lastname: Takeuchi
authors.forename: Satoru
authors.initials: S
authors.lastname: Takahashi
authors.forename: Tadaichi
authors.initials: T
authors.lastname: Kitamura
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000378:metabolism / Q000627:therapeutic use*; D002394:Catechol O-Methyltransferase / Q000235:genetics* / Q000378:metabolism; D018450:Disease Progression; D018572:Disease-Free Survival; D004961:Estramustine / Q000378:metabolism / Q000627:therapeutic use*; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008297:Male; D008715:Methionine / Q000235:genetics; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011355:Prodrugs / Q000378:metabolism / Q000627:therapeutic use; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics; D014633:Valine / Q000235:genetics
chemical_list: D018931:Antineoplastic Agents, Hormonal; D011355:Prodrugs; D004961:Estramustine; D008715:Methionine; D002394:Catechol O-Methyltransferase; D017430:Prostate-Specific Antigen; D014633:Valine